X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FRESENIUS KABI ONCO. - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FRESENIUS KABI ONCO. PANACEA BIOTECH/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 80.7 22.1 364.7% View Chart
P/BV x 1.8 3.1 57.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs149176 84.5%   
Low Rs8279 104.8%   
Sales per share (Unadj.) Rs84.137.7 223.3%  
Earnings per share (Unadj.) Rs-18.35.1 -359.4%  
Cash flow per share (Unadj.) Rs-6.76.7 -99.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.742.5 196.8%  
Shares outstanding (eoy) m61.25158.23 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.4 40.7%   
Avg P/E ratio x-6.325.0 -25.3%  
P/CF ratio (eoy) x-17.218.9 -91.1%  
Price / Book Value ratio x1.43.0 46.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,07420,135 35.1%   
No. of employees `0002.81.2 238.7%   
Total wages/salary Rs m1,449703 206.1%   
Avg. sales/employee Rs Th1,874.15,176.2 36.2%   
Avg. wages/employee Rs Th527.0610.4 86.3%   
Avg. net profit/employee Rs Th-407.7699.6 -58.3%   
INCOME DATA
Net Sales Rs m5,1545,963 86.4%  
Other income Rs m10018 554.4%   
Total revenues Rs m5,2545,981 87.8%   
Gross profit Rs m-7661,430 -53.6%  
Depreciation Rs m711258 275.7%   
Interest Rs m1,503-26 -5,780.8%   
Profit before tax Rs m-2,8811,216 -236.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-68 -2,600.4%   
Tax Rs m17342 4.9%   
Profit after tax Rs m-1,121806 -139.1%  
Gross profit margin %-14.924.0 -62.0%  
Effective tax rate %-0.628.1 -2.1%   
Net profit margin %-21.813.5 -161.0%  
BALANCE SHEET DATA
Current assets Rs m3,8105,102 74.7%   
Current liabilities Rs m8,3652,385 350.7%   
Net working cap to sales %-88.445.6 -194.0%  
Current ratio x0.52.1 21.3%  
Inventory Days Days156150 103.8%  
Debtors Days Days67113 59.3%  
Net fixed assets Rs m14,4805,148 281.3%   
Share capital Rs m61158 38.7%   
"Free" reserves Rs m9036,556 13.8%   
Net worth Rs m5,1276,732 76.2%   
Long term debt Rs m5,832952 612.4%   
Total assets Rs m19,43310,388 187.1%  
Interest coverage x-0.9-45.8 2.0%   
Debt to equity ratio x1.10.1 804.1%  
Sales to assets ratio x0.30.6 46.2%   
Return on assets %2.07.5 26.2%  
Return on equity %-21.912.0 -182.7%  
Return on capital %3.614.6 24.9%  
Exports to sales %24.574.5 32.9%   
Imports to sales %10.224.8 41.1%   
Exports (fob) Rs m1,2644,441 28.5%   
Imports (cif) Rs m5251,477 35.5%   
Fx inflow Rs m1,5395,298 29.1%   
Fx outflow Rs m9421,772 53.2%   
Net fx Rs m5973,525 16.9%   
CASH FLOW
From Operations Rs m5991,274 47.0%  
From Investments Rs m-438-1,204 36.4%  
From Financial Activity Rs m-303-196 154.3%  
Net Cashflow Rs m-141-126 111.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 9.6 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 42,599 24.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 21, 2017 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS